GlassScriptPhysician profile
Walid El Ayass
NPI 1700078250
$111,163.58
in general payments reported to CMS, 2019-2025
47 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,296 · 2020: $935 · 2021: $932 · 2022: $1,540 · 2023: $36K · 2024: $47K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $85K · Travel and Lodging: $9,089 · Food and Beverage: $6,210 · Consulting Fee: $5,393 · Education: $69.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $84,700.00 |
| Travel and Lodging | $9,088.66 |
| Food and Beverage | $6,210.02 |
| Consulting Fee | $5,392.50 |
| Education | $69.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $79,229.42 | 2020-2025 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $19,379.55 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Novartis Pharmaceuticals Corporation | $2,361.19 | 2019-2025 | |
| Astrazeneca Uk Limited | $1,665.00 | 2025 | |
| Daiichi Sankyo INC. | $928.97 | 2022-2025 | Datroway, Injectafer, Enhertu |
| Glaxosmithkline, LLC. | $567.39 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $504.96 | 2021-2025 | Trodelvy |
| Pfizer INC. | $457.93 | 2019-2025 | |
| Seagen INC. | $448.36 | 2022-2023 | Tukysa |
| Janssen Biotech, INC. | $425.73 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Celgene Corporation | $405.33 | 2019-2023 | Opdualag |
| Merck Sharp & Dohme LLC | $402.61 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genentech USA, INC. | $381.15 | 2019-2025 | Phesgo, Itovebi, Perjeta |
| Puma Biotechnology, INC. | $353.42 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $351.67 | 2019-2025 | Opdivo |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walid El Ayass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.